RMTG Launches New Fellowship in Point-of-Care Regenerative Medicine
News related to:Regenerative Medical Technology Group, Inc · 1 min read
Regenerative Medical Technology Group, Inc. (RMTG) has launched a new fellowship program through its ISSCA division aimed at training physicians in point-of-care regenerative medicine. The fellowship, which is part of ISSCA's most comprehensive educational credential, integrates regenerative medicine, biotechnology, longevity medicine, and artificial intelligence (AI).
The new program, designed to be a multi-component educational offering, is intended to deepen relationships with RMTG's physician network. It is part of the company's broader strategy to provide advanced educational modules and technology-enabled clinical tools, including ISSCA AI™, to its network of healthcare professionals.
According to David Christensen, CEO and President of RMTG, the fellowship is a response to the evolving landscape of clinical practice.
RMTG's ISSCA division has been operating physician-education programs for over 15 years. The company reports that more than 12,000 physicians have been trained through its programs, and its network now reaches over 30 countries. However, the figures provided are aggregated and do not represent current paying subscribers to ISSCA AI™ or enrollment in the new fellowship.
The fellowship curriculum is designed to integrate regenerative medicine, emerging biotechnology, longevity medicine, clinical implementation, and AI. ISSCA AI™, the physician-controlled clinical-intelligence platform, is intended to assist participating physicians with structured clinical-data review and workflow support while maintaining clinical decision-making autonomy.
Christensen emphasized that the fellowship serves as one educational onboarding channel for ISSCA AI™.
RMTG, operating through its Global Stem Cells Group and subsidiaries, combines physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technology across an international network in permitted markets. The company operates in more than 30 countries and continues to expand its reach and influence in the regenerative medicine sector.
The launch of the fellowship is part of RMTG's broader strategy to stay at the forefront of regenerative medicine and AI-driven clinical tools. As the field continues to evolve, the company aims to provide its physician network with the comprehensive training and tools necessary to deliver innovative regenerative solutions to patients.